Simvastatin in the Prevention of Recurrent Pancreatitis
Status:
Recruiting
Trial end date:
2022-09-28
Target enrollment:
Participant gender:
Summary
Recurrent acute pancreatitis and recurrent relapses of inflammation in chronic pancreatitis
are an important problem. In some cases, prevention of these acute flares of inflammation is
not possible. Population-based studies and meta-analysis of randomized controlled trials
suggest that statins may decrease the incidence of acute pancreatitis. SIMBA aims to
investigate the effect of simvastatin on the incidence of new episodes of pancreatitis in
recurrent acute pancreatitis and chronic pancreatitis. This is a non-profit,
researcher-driven placebo-controlled multicenter (27 Spanish centers) randomized controlled
trial
Phase:
Phase 3
Details
Lead Sponsor:
Enrique de-Madaria
Collaborators:
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana Generalitat Valenciana Instituto de Salud Carlos III